(Q43809187)

27 November 2017

title

Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis (English)

1 reference

27 November 2017

main subject

visceral leishmaniasis

1 reference

1 reference

Maria Agallou

1

1 reference

27 November 2017

Despina Smirlis

series ordinal

2

1 reference

27 November 2017

Ketty P Soteriadou

series ordinal

3

1 reference

27 November 2017

Evdokia Karagouni

series ordinal

4

1 reference

27 November 2017

language of work or name

English

0 references

publication date

13 June 2012

1 reference

27 November 2017

1 reference

27 November 2017

volume

30

1 reference

27 November 2017

issue

34

1 reference

27 November 2017

page(s)

5086-5093

1 reference

Immunity and immunosuppression in experimental visceral leishmaniasis.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Identification and characterization of T cell-stimulating antigens from Leishmania by CD4 T cell expression cloning

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

The nucleosome: from genomic organization to genomic regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Expression of a novel Leishmania gene encoding a histone H1-like protein in Leishmania major modulates parasite infectivity in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Identification of a histone H1-like gene expressed in Leishmania major

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Leishmania histone H1 overexpression delays parasite cell-cycle progression, parasite differentiation and reduces Leishmania infectivity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Antigenicity of the Leishmania infantum histones H2B and H4 during canine viscerocutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Characterization of the antigenic determinants of the Leishmania infantum histone H3 recognized by antibodies elicited during canine visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Mapping of the linear antigenic determinants from the Leishmania infantum histone H2A recognized by sera from dogs with leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Evolutionarily conserved proteins as prominent immunogens during Leishmania infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunobiology of dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

The dendritic cell system and its role in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Dendritic cell-based immunotherapy combined with antimony-based chemotherapy cures established murine visceral leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

ISCOMs vaccine against experimental leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunohistological features of visceral leishmaniasis in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient to mediate protection to an infectious parasite challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing Leishmania infantum p36/LACK and IL-12 in combination with purified p36.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

A single intradermal administration of soluble leishmanial antigen and plasmid expressing interleukin-12 protects BALB/c mice from Leishmania major infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Protection against cutaneous leishmaniasis in outbred vervet monkeys using a recombinant histone H1 antigen.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Infection pattern and immune response in the spleen and liver of BALB/c mice intracardially infected with Leishmania donovani amastigotes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Modulation of CD11C+ splenic dendritic cell functions in murine visceral leishmaniasis: correlation with parasite replication in the spleen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immunization with H1, HASPB1 and MML Leishmania proteins in a vaccine trial against experimental canine leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Immune response against Leishmania antigens in dogs naturally and experimentally infected with Leishmania infantum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

The capacity to produce IFN-gamma rather than the presence of interleukin-4 determines the resistance and the degree of susceptibility to Leishmania donovani infection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Organ-specific immune responses associated with infectious disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Inhibition of IL-2 induced IL-10 production as a principle of phase-specific immunotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Interleukin-13 in Iranian patients with visceral leishmaniasis: relationship to other Th2 and Th1 cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

IL-10 AND IL-12 ARE THE MAIN REGULATORY CYTOKINES IN VISCERAL LEISHMANIASIS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.075

10.1016/J.VACCINE.2012.05.075

7 January 2021

Identifiers

DOI

1 reference

27 November 2017

1 reference